Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Plus Cryoablation vs Cryoablation Alone for Early-Stage NSCLC
NCT06580665Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of serplulimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-Free Survival at 3 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06580665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580665.